Endometrioma treatment involves trade-offs between symptoms, recurrence, ovarian reserve and fertility plans. Ethanol sclerotherapy is one approach under investigation and use in selected settings. It should not be presented as a universally safer substitute for surgery or a proven way to improve live birth.
Endometrioma management has long involved a tension between treating disease and protecting ovarian tissue. A visible cyst has never been sufficient, by itself, to settle every surgical decision.
Ethanol sclerotherapy is discussed as an alternative in selected settings. Its promise should be assessed alongside comparative evidence and long-term outcomes.
The approach involves aspiration and a sclerosing agent, with protocols varying. It is not a simple guarantee to drain, burn and resolve a cyst.
The reason this approach is being revisited is clear: the preservation of ovarian function is paramount.
Surgery can affect ovarian reserve. That risk matters, but reserve markers are not a complete measure of reproductive potential.
Avoiding excision does not guarantee preservation or establish a superior live-birth outcome. Comparisons need attention to study design, patient selection and recurrence.
However, viewing this treatment as a panacea is dangerous. It carries distinct limitations:
- Incomplete Eradication: The lesion is not fully excised; the risk of recurrence remains a persistent reality.
- Symptom Management: Endometriosis is a complex disease involving deep-pelvic inflammation, nerve involvement, and adhesions. Sclerotherapy may fail to provide sufficient relief for patients suffering from severe chronic pain.
- Safety and diagnosis: Suspicious findings need appropriate evaluation. Aspiration is not equivalent to excised tissue for histology, and leakage and other procedural risks also matter.
Ultimately, the dilemma boils down to a single question: What is our priority? Is it pain relief, long-term recurrence prevention, or the preservation of ovarian function?
Symptoms, suspicious findings, reserve, prior surgery and fertility plans can lead to different recommendations. Age alone does not make sclerotherapy the default.
The paradigm of endometrioma treatment is quietly shifting from “remove what you see” to “how do we preserve what remains?”
A compromise can be reasonable when its goals and uncertainties are explicit. No technique should be described as ensuring the least reproductive loss in every case.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.
Guidance and uncertainty
Management should distinguish symptom treatment, ovarian reserve and fertility outcomes. Emerging approaches need appropriate comparative evidence. ESHRE guideline: endometriosis (2022).
Related reading
Endometrioma Sclerotherapy: Can Alcohol Treatment Help Spare the Ovary?